Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Lorlatinib,LRLT2023-US,2023,USA,MDV,350,62,45.0,55.0,26.5,60.0,85.0,5.0,15.0,35.0,30.0,20.0,40.0,30.0,20.0,10.0,20.0,35.0,30.0,12.0,5.0,3.0,7.0,4.0,25.0,40.0,30.0,Cisplatin + Pemetrexed,Carboplatin + Paclitaxel,Vinorelbine + Cisplatin,Docetaxel + Carboplatin,0.0,0.0,0.0,20.0,50.0,60.0,15.0,45.0,40.0,70.0,2
Lorlatinib,LRLT2022-EU,2022,Germany,Claim Database,420,68,38.0,62.0,27.1,55.0,78.0,8.0,12.0,38.0,32.0,18.0,35.0,32.0,23.0,10.0,18.0,32.0,35.0,15.0,7.0,4.0,9.0,5.0,22.0,38.0,28.0,Cisplatin + Gemcitabine,Carboplatin + Pemetrexed,Vinorelbine + Carboplatin,Docetaxel + Cisplatin,0.0,0.0,0.0,18.0,48.0,58.0,18.0,42.0,40.0,65.0,3
Lorlatinib,LRLT2024-Asia,2024,Japan,MDV,280,65,42.0,58.0,25.8,48.0,82.0,6.0,14.0,36.0,31.0,19.0,38.0,29.0,21.0,12.0,19.0,34.0,32.0,13.0,6.0,3.5,8.0,4.5,24.0,39.0,29.0,Cisplatin + Docetaxel,Carboplatin + Gemcitabine,Vinorelbine + Docetaxel,Pemetrexed + Cisplatin,0.0,0.0,0.0,19.0,49.0,59.0,16.0,44.0,40.0,68.0,2.5
